The Serendipity Collective 2024 Challenge

A Gateway to
Revolutionary Ideas

The stage is set for the unveiling of the Serendipity Collective 2024 Global Challenge, proudly presented by IdeatePlus and sponsored by ONR Global.

Serendipity Collective 2024 Global Challenge: A Melting Pot of Futuristic Visions

At its core, the Serendipity Collective is more than a challenge; it’s a visionary confluence. Here, researchers from a myriad of disciplines converge to share their dreams for the future of science, society, and humanity. This year’s edition sharpens focus on specific themes, yet retains its foundational ethos: a cradle for ideas that reimagine what lies ahead. Reflecting on last year’s success, which saw over 70 proposals and funding of $50,000 each for three teams, the challenge stands as a testament to innovation addressing regional and global concerns.

Read more about the Collective →

Synergy and Goals

Uniting Forces for Greater Impact

Our ambition is to cultivate a dynamic community, primed to address not only the challenges set forth by ONR Global but also broader global issues. This union is a deliberate move to bridge the gaps in a research world often compartmentalized into silos. By fostering cross-disciplinary collaboration, we aim to catalyze a wave of revolutionary change.

The Culmination Event: A Gathering of Minds in Estonia

The journey culminates in an extraordinary pitching event set to take place in Estonia in May. This will be a historic convergence of some of the brightest minds, collectively reimagining the future of naval operations and carving pathways for global well-being.

The Ambitious Objective: Empowering Innovators Through Grants

Our mission is bold: to award research grants to as many as six teams from this combined challenge. Beyond financial support, the event promises an enriching experience, offering networking opportunities with approximately 100 esteemed figures over four days, all in an environment that nurtures collaboration and support.

Invitation and Partnerships

Partner with Us: A Call to Innovate and Transform

We invite you to partner with us and the Office of Naval Research Global (ONRG). This is an opportunity to connect with the brightest minds emerging from the Serendipity Collective. As partners, you will play a crucial role in aiding innovators to morph their groundbreaking ideas into tangible realities, while gaining significant global exposure and uncovering transformative opportunities.

A Rallying Cry for Innovators

As we embark on this journey, we eagerly anticipate the novel ideas and collaborations that these challenges will foster. Together, let us shape a future that is not only imagined but actively created. Join us as we innovate for a better tomorrow.

THE 2024 WINNERS

Reshaping the future of healthcare with Virtual Humans

Idea Owner: Marina Kovačević

Imagine a future where healthcare is not just reactive but proactive—where we prevent diseases before they even arise. To achieve this, we need to keep only one thing in mind: Each human is unique and needs to be treated as such. In today’s landscape, it is clear that medications don’t deliver consistent results for everyone.

That is why there is a growing momentum behind personalized medicine. However, the challenge lies in the limitations of current approaches, which fail to capture the intricate complexities of human biology. This gap in understanding often results in treatments that fall short of expectations, leaving patients without the optimal care they deserve. To achieve truly personalized medicine, we need to find an ethical, sustainable way for medical professionals to test assumptions, checking if proposed treatment will work for a particular patient — before any drug enters the patient’s body. To achieve this dream and revolutionize wellbeing and longevity of the human race we propose the development of a Virtual Human (Digital Twin Platform) – a virtual testing ground that will allow personalized medicine to become a reality. We plan to create a platform that will allow creation of digital replicas of a human being – digital twins – with the ability to predict future diseases, simulate results of different treatments, thus predicting outcomes and giving healthcare providers a tool to help them define a perfect treatment without any harm to the real human.

This will allow an unprecedented level of personalization in medicine, since only the treatment with the highest probability of success will actually be applied. Digital twins will encapsulate all the major properties of a real human. For this, we will use comprehensive data sets (laboratory results, imaging scans, medical history, etc – all pertinent patient medical information available).

Virtual humans will be dynamic models, encapsulating unique physiological and pathological characteristics of each patient and simulating reaction of the digital body to various treatments. Besides this, we can also add data related to the environmental factors and inner-workings of specific individuals. This data, regarding their activities, location, weather conditions, and various other factors can be tracked through everyday applications—such as health and fitness trackers, social media activity and even sentiment analysis. With all of this, we have the potential to reconstruct a comprehensive, hierarchical temporal network in the bio-cyber-physical-info domain of that individual. By incorporating such detailed data into our platform, we can anticipate future states and behaviors with remarkable accuracy, reflecting the evolving health status of the specific individual.

This integration of continuous data ensures that our Virtual human remains up-to-date and accurately mirrors the patient’s current condition. By leveraging advanced computational techniques, including network reconstruction methodologies, we can predict future trajectories not only of isolated health parameters but of the entire contextual landscape surrounding the individual. This means we’re not just analyzing individual time series; we’re exploring the intricate interplay and influences across various domains—biological, cyber, physical, and informational.

We are not only simulating the response of a digital body to various treatments but also foreseeing how external factors and individual activities might shape their health journey. This holistic understanding will allow us to tailor treatment strategies with unprecedented precision, optimizing patient outcomes and resource allocation. In essence, we are not just creating digital twins; we are constructing dynamic, predictive models that encapsulate the complexity of human life in its entirety. By integrating cutting-edge computational techniques with real-time data streams, we are not only revolutionizing personalized medicine but potentially reshaping the future of healthcare itself.

Key Aspects: Multiscale Modeling: Utilizing cutting-edge techniques such as Molecular Dynamics for atomic-scale representation, Reaction Diffusion Simulations for cell-scale dynamics, and Agent-Based Modeling for tissue-scale interactions, we will construct intricate models of specific organs. To unify disparate organ models into a cohesive system – A whole body model, we will leverage abstract mathematical frameworks, like hierarchical, temporal complex networks, establishing connections and interactions between various physiological processes.

Continuous Data Integration: Integration of (pseudo) real-time data from monitoring (routine checkups, wearables, activity tracking devices, real-time monitoring devices, etc) will ensure that the digital twin remains up-to-date and accurately reflects the patient’s evolving health status.

Evolutionary AI for Drug Discovery: A pivotal component of our system is evolutionary AI algorithms to predict future disease trajectories and identify optimal treatment strategies. This algorithm will enable a digital body to change over time, allowing medical professionals to effectively “see into the future” and even simulate multiple possible futures, based on the proposed treatments. By anticipating disease progression and preemptively selecting the most effective medications, we aim to transform once-deadly diseases, such as cancer, into manageable conditions.

Human-on-a-chip: We can develop a human-on-a-chip model where we can take cells from patients to create a dynamic model where we can test in advance the treatments from our platform.

Ethical aspects: A special care will be given to security and ethical aspects of the system. We are aware how delicate this topic is and we will ensure responsible and effective implementation of the human digital twins. Based on our previous research, we believe tumors are the perfect initial step. Their significance, abundance of clinical data, rapid changes suitable for quick testing and complexity makes them a perfect starting point for our system. By demonstrating the feasibility and efficacy of our approach in managing such complex things as cancer, we will establish a robust proof of concept that can be extrapolated to other diseases.

Digital Twin-Based Personalized Medicine represents a paradigm shift in healthcare delivery, offering tailored treatment solutions that optimize patient outcomes and resource utilization. By harnessing the power of computational modeling, revolutionary artificial intelligence, and interdisciplinary collaboration, we have the potential to transform the landscape of medicine and pave the way for a future where diseases are not only treatable, but also preventable.

Transforming the polymer industry with bio-based, self-healing vitrimers

Idea Owner: Birgitta Ebert

Thermoset resins are highly cross-linked polymers renowned for their superior mechanical properties, thermal stability, and resistance to chemicals, making them indispensable in aerospace, automotive, and electronics industries.

However, their irreversible curing process and resistance to degradation pose significant environmental challenges, as they contribute to persistent plastic pollution and are difficult to recycle. This highlights the urgent need for more sustainable material solutions. Vitrimers are a novel polymer class that merges the beneficial traints of thermoplastics and thermosets, simultaneously addressing some of their inherent limitations. Characterized by dynamic molecular networks capable of topological rearrangement without altering the overall bond count, vitrimers retain network connectivity under thermal conditions, demonstrating viscoelastic properties without dissolving—unlike thermoplastics, which melt and flow upon heating. Moreover, in contrast to thermosets, which become unprocessable post-curing, vitrimers maintain their ability to undergo reversible molecular configuration changes without compromising the integrity of the covalent network. This unique behaviour stems from Covalent Adaptive Networks (CANs) that facilitate structural reconfigurations trough bond exchange reactions (e.g., transesterification, transamination) while maintaining the overall covalent network.

This adaptability allows for self-healing, recyclability, and weldability, positioning vitrimers for diverse applications in electronics, biomedical, and sustainability sectors where mechanical resilience is paramount. Nevertheless, the synthesis of vitrimers is not without its difficulties, especially in precisely adjusting catalyst concentrations and reactant ratios to refine the properties of the materials. Vitrimers offer the potential to match or even exceed the performance of some thermosets in specific conditions, while also providing the significant benefits of recyclability and moldability. The optimization process typically requires a careful trade-off among various material characteristics, including strength, durability, and the ability to be reprocessed, to suit specific applications.

Current research is focused on overcoming these challenges, especially through addition of nanofillers to enhance the mechanical strength of resin. However, the incorporation of nanofillers into polymers presents its own set of challenges, such as achieving uniform dispersion of nanoparticles within the polymer matrix to prevent agglomeration. Furthermore, ensuring compatibility between the nanofillers and the polymer base is crucial for optimizing the composite’s performance and ensuring its practical applicability, necessitating careful selection and modification of both fillers and polymers. This research project seeks to lead the development of fully bio-based vitrimers, by utilizing renewable biological components, thus promoting promoting environmentally sustainable polymers.

We plan to develop one pot vitrimer nanocomposite, while overcoming the challenges concerning achieving a high dispersion quality of nanoparticles in the polymer, the selection of right type of nanofiller with desirable surface functionality, as well as the cost associated with the production of nanoparticles. This project will harness enzymes for mediating and controlling dynamic exchange reactions. It has recently been shown that it is possible to use lipase to catalyse transesterification reactions in vitrimer synthesis and the repeated polymer network restructuring at temperatures of up to 100 °C.

The use of enzymes avoids the use of potentially environmentally harmful catalysts and enables polymer malleability at reduced temperatures. Moreover, we envision the integration of these enzymes (e.g., lipases, aminotransferases) onto microbial cell platforms, such as filamentous fungi or spores, which not only serve as catalyst support but also act as functional filler materials to biobased epoxy resins to augment the mechanical properties of the vitrimers. Mycelium, known for its robust and lightweight structure, offers the potential for improving polymer strength and durability, while the use of spores could introduce additional functional benefits, such as thermal stability.

This innovative approach combines biotechnology with materials science, promising sustainable solutions across industries, from soft robotics to aerospace. Specifically, we aim to produce durable, self-healing vitrimer materials for use in harsh conditions, such as space or marine environments, by exploiting the synergy between bio-catalysis and bio-based fillers. This could lead to breakthroughs in material science, offering sustainable alternatives and advancing our commitment to environmental sustainability.

THE 2024 SHORTLIST

CELLTRONIC

Idea Owner: Amparo Pascual-Ahuir

Celltronic is a groundbreaking project aimed at creating bionic cells for space colonization.

In an era where space exploration and settlement are becoming increasingly feasible, it is imperative to develop innovative solutions for adapting life forms to the harsh conditions of space environments. Celltronic proposes the substitution of organic cellular elements with inorganic components to enable microorganisms’ adaptation to gravitational forces, radiation, extreme temperatures, and resource scarcity.

Objective: The primary objective of Celltronic is to merge biology with electronics at the cellular level. By incorporating inorganic parts into living cells, these bionic cells will acquire characteristics that facilitate survival in inhospitable environments. Retaining the organic components will endow the bionic cells with the ability to reproduce, regenerate, and even evolve in these challenging environments.

Methodology: Celltronic will develop bionic cells by employing cutting-edge techniques from synthetic biology, bioengineering, and nanotechnology. Initially, researchers will identify key organic cellular components that can be replaced with inorganic substitutes without compromising cell function. Next, precise methods for integrating these components into living cells will be devised, ensuring minimal disruption to cellular processes.

Through iterative experimentation and optimization, Celltronic aims to create a diverse catalog of cellular implants tailored for various applications. Celltronic represents a paradigm shift in biological sciences, offering transformative solutions for space exploration and beyond. By harnessing the power of bionic cells, humanity can overcome the challenges posed by hostile environments and pave the way for sustainable space colonization.

Reproductive Longevity through Microbiome Modulation

Idea Owner: Ronny Szelinsky

We want to solve real global challenges – and the biggest challenge of the next 50 years will be the massive decline in birth rates & shrinking population sizes.

In the next 50 years, populations of India, Japan, Italy, Germany and 25 other countries are expected to reduce by 50%. A main reason for these declining fertility rates is a higher average age for the first pregnancy, connected to fertility hurdles. But why not getting pregnant in the 30s or 40s? We identified the reproductive microbiome as a main driver for age related infertility – so we are developing the first microbiome reproduction platform to spin out a therapeutic that impacts immunologic reactions in the reproductive tissues by building up selected bacterial & metabolite materials. A groundbreaking approach that helps women to overcome fertility issues & extend the reproductive lifespan with the help of their microbiome.

Im-PLANT-ing Brains

Idea Owner: Marco Rinaudo

Plants have shaped our world since before we’ve been even started walking on it. To date, they still represent the most valuable asset for human survival and for our future, especially in the face of the incumbent world challenges (pollution, clean food, growing population, diseases and more). Plants have evolved multiple molecules which impact the human physiology and multiple inter-plants communication mechanisms. Among these, little is known about plant-derived extracellular vesicles (ExoPlant), even less is known about their content and function and far more less, almost nothing, on their effect on the human brain physiology. The aim of our project is to evaluate the potential of ExoPlant to impact mammalian brain physiology in both healthy and disease states using a non-invasive administration route (i.e. intranasal administration) which impact mainly the brain. Results from our project could unravel novel phytotherapeutic molecules, such as novel microRNAs, able to modulate neuronal and glial function, paving the way to the development of innovative therapeutic strategies. Furthermore, it would push the farming methods toward hydroponic cultivating systems, which have multiple advantages compared to common farming methods

Circular Economy Marine Bio Factory

Idea Owner: Sofia Ferreira

Groundbreaking fully integrated bioprocess to transform seawater plastic waste into bioproducts.

Discovery and selection of the best halophilic microorganism and development of synthetic biology tools to allow the biotransformation of plastic waste into valuable bioproducts such as biofuels or fine chemicals. This aim involves the utilization of genetic and computational tools to construct and optimize the microbial chassis and the DNA parts fully adapted to the marine environment.

We envision developing a ready-to-use integrated bioprocess from waste to bioproducts that can be straightforwardly installed in any coastal area that involves pretreatment, bioprocess and downstream processing. The impact of this project will be on sustainability by offering a novel solution to seawater pollution.

Currently there are no technical options available to convert plastics into products. Furthermore, by avoiding the inland transportation of plastics and the use of freshwater, we believe this proposal provides an economic solution to this global challenge.

Next-gen antimicrobial animal feed additives

Idea Owner: Nasim Amiralian

The use of antimicrobials in agriculture has facilitated intensive livestock production, essential to meet the global demand for animal protein. However, the widespread use of antimicrobials in farming is promoting antimicrobial resistance, affecting both animal and potentially human health.

Environmentally friendly alternatives such as vaccines, probiotics, prebiotics, bacteriocins and antimicrobial peptides have been proposed to reduce reliance on antimicrobials. However, these alternatives face several challenges, including variable efficacy, with some not as effective as traditional antimicrobials, high costs and limited effectiveness against a broad spectrum of pathogens. Furthermore, the education and training of farmers are crucial for the effective adoption of these alternatives. Triterpenoids, a class of natural compounds found in various plants, have garnered attention for their potential antimicrobial properties due to their effects against various pathogens, including bacteria, fungi, and parasites. These compounds are known to disrupt microbial cell membranes, inhibit specific enzyme activities, and modulate immune responses, potentially enhancing gut health by promoting beneficial gut microbiota.

In addition, triterpenoids have also been shown to reduce methane formation in cattle, a significant source of agricultural greenhouse gas emissions. However, commercial application of triterpenoids is impeded by the limited accessibility of these compounds, often found in low concentrations and in complex mixtures of similar molecules.

Traditional extraction techniques of the low abundant molecules from plant material often involve the use of substantial quantities of solvents, leading to resource-intensive and unsustainable practices. Moreover, mass extraction has significantly impacted native species, resulting in the endangerment or extinction of many medicinal plants, not only contributing to a loss of biodiversity but also threatening drug discovery. Furthermore, the complex structure of triterpenoids makes chemical synthesis an unfeasible alternative.

To address this issue, we have demonstrated the synthesis of various triterpenoids in genetically modified yeast. This approach not only provides a sustainable source of triterpenoids but also opens avenues for creating novel compounds with tailored properties, overcoming the traditional limitations of natural extraction, and facilitating broader industrial applications. A major disadvantage of triterpenoids is their high hydrophobicity, which severely limits their bioavailability and thus their efficacy. To overcome this hurdle and regulate the delivery of triterpenoids in animal bodies, we propose to utilise cellulose nanofibres, a renewable and eco-friendly material obtained from biomass residuals, as a template to attach triterpenoids and as an additive to animal food.

We have shown that the nanostructure of cellulose fibres provides a high specific surface area, and its hydrophobicity, surface charge and porosity can be tuned by different surface modifications, thereby enhancing the triterpenoids’ bonding to cellulose nanofibers and their stability under different environmental conditions, such as variations in pH, temperature, and humidity during the animal food processing, and in the animal digestive tract. In addition, triterpenoids tethered to cellulose nanofibers will be immobilised, yielding their controlled release and increased durability.

In summary, our innovative approach of synthesising triterpenoids in genetically modified yeast, coupled with the strategic utilisation of cellulose nanofibers to regulate their delivery in animal foods and bodies, signifies a groundbreaking step towards sustainable and efficient antimicrobial alternatives. The proposed products surpass the constraints of natural extraction by providing a renewable source of triterpenoids and ensuring enhanced stability and controlled release of these compounds, promising significant advancements in animal health and broader industrial applications.

Our food can finally be our medicine

Idea Owner: Bojana Blagojevic

Using food as medicine is an approach as old as humanity. Despite all the advances in this field, nowadays, non-communicable diseases and food-related health conditions, such as cardiovascular diseases, diabetes, and cancers, cause over 70% of all deaths globally and present the biggest burden for the healthcare system.

What do we do wrong? For food to be claimed as healthy, the only representative criterion is its effect on human organism. Looking that way, food ingredients cannot be claimed as healthy without the additional information – ’for whom?’. We now know that human response to certain food is highly individual so, the traditional one-size-fits-all approach is not an option anymore. Our interaction with food is a two-way street.

Our body carries the information on how we are going to digest and process the food, but reversely, food components and digestion products influence and modulate the behavior of our body, which gives power to both, the humans, and the food. Imagine that you can eat food that is designed specifically for your unique needs, optimizing your health and well-being.

We want to initiate a new era of food production with a groundbreaking platform that unifies food matrix data, food-genes and food-gut microbiota interactions, and translates it to guidelines for food producers for the development of Precision Food products.

Creating Precision Food products needs to start by taking into account personal characteristics: age, sex/gender, genetics, epigenetics, gut microbiome, lifestyle, and personal preferences. At the same time, we need to know the composition of the food matrix that reaches the body, its source, structure, chemistry, effects of processing techniques, and ingredients interactions.

Leveraging accumulated knowledge and future achievements in all aforementioned disciplines, together with biosensors, AI technologies, and predictive modelling techniques, can result in Precision Food products, i.e. food products tailored for specific population groups, that can really be used as medicine, or even in some cases, instead of medicines.

Precision Food will be able to control and manage our organism behavior, activate ‘good’ genes, snooze or deactivate the ‘bad’ genes, to modulate our microbiome, thus preventing/controlling the development of certain diseases. To help us feel better, think better, live better, and stay healthy.

Microplastic Biosensors

Idea Owner: Yemi Ayankunle

Microplastics (MPs) are everywhere. In our food, in our cup, in our surrounding environment, and even in our blood. .

We have known this for years and with global plastics production rising rapidly each year it’s time to ask “How much is too much?”. The answer is as relevant as it is complicated.

The main challenge is finding the right methodology that would be the most impactful, accurate, and specific because even a simple plastic bottle can contain several different polymer layers. Waste treatment facilities are a major point source of MPs to the environment, with wastewater treatment plants (WWTPs) serving as major conduits for their dispersal. We can measure and quantify MP types and concentrations entering and exiting WWTPs through comprehensive wastewater sampling. Employing harsh chemicals such as a Fenton reagent with a 30% concentration of H2O2, we digest organics, filter the solution, and meticulously examine the retentate under a stereo microscope for MP categorization.

Suspected MPs undergo further scrutiny using FTIR for chemical composition characterization. However, this process of MP identification and quantification is undeniably time-consuming, prompting our exploration of innovative bio-sustainable solutions such as biosensors capable of swiftly and accurately detecting target MPs in various sample matrices, including blood samples, with minimal or no digestion required.

Our mission is clear: reduce microplastic (MP) concentrations entering water bodies and estimate the amount of microplastics found in human tissues and blood.

Our solution is to develop and improve a method for analyzing all these polymers regardless of the plastic species and sample type.

The platform consists of three parts:
1. Uniformal sample collection and preparation methodology for water, air, soil, environmental and biological samples.
2. Definitive analysis of plastic species
3. Quantitative analysis of each specific plastic

For developing the platform we will employ biological, chemical, microscopy, spectroscopy, and imaging techniques that make up the core competence of our team and our technology platform.

The goal of the platform is to shed light on how microplastics affect humans and will enable us to determine healthy levels and associate disease risk with the type and amount of microplastics found in human tissues and blood.

As an application example, we’re pioneering the development of microfilters tailored to capture microfibers shed during laundry wash cycles. Studies highlight microfibers as the predominant MPs entering and leaving WWTPs, making this innovation pivotal in our quest to mitigate microplastic pollution at its source.

Understanding Biology Using Modern AI

Idea Owner: Felix Kamieth

The modern approaches in AI for utilizing Deep Learning to solve mathematical modeling challenges have transformed many different fields, starting with Image Detection and Natural Language Processing, just recently moving into protein folding and weather prediction.

The latest developments here have been generative models, the most prominent being language generation like chatGPT and image generation using text inputs like DALL-E and Stable Diffusion. These approaches make use of large sums of data and the rise of GPU computational power to create artificial intelligence systems capable of finding patterns where prior approaches have failed.

The approach of this project is to use what has been developed so far in AI, develop it further and use it to solve one of the biggest scientific mysteries, the emergence of complex life from a single cell. The field of biology has been transformed into a big data field of its own.

New automated data gathering techniques like single cell sequencing are giving insights into the complexity of life at an unprecedented scale and resolution. However, ever since the beginning of genetic sequencing, the amount of data has outpaced our ability to make sense of it.

One major inspiration is the field of artificial life, and it is our conviction that – especially in biology – it has a lot to offer to advance the application of AI as well as improve its foundations in terms of efficiency and reliance on data.

State of the Art and what to expect
The current state of the art in Artificial Intelligence is being pushed forward by so-called foundation models based of a subset of novel architectures best suited to make use of the now available large resource, both in terms of computation and data. These models are currently built either based on a transformer architecture or a latent diffusion architecture with a massively oversized parameter count a the order of magnitude of 175 Billion parameters in the case of GPT3, to raise a recent example. These models are then trained (pre-trained) on large datasets usually sampled from internet sources.


The models show emergent properties which grow with parameter size. They manage to generalize beyond their training data in fields like text and image generation. It is still common practice to take these pretrained foundation models and train them on a smaller dataset about a specific problem to further improve results. However modern foundation models show the ability to learn patterns from a few examples provided in the input (the so-called prompt). With the recent practice of prompt engineering this is a field to optimize the results produced by good prompts.

This leads – in the limit – to the replacement of fine-tuning by prompt engineering. With this upside one can consider the use of such models on biological data and this has already shown to lead to impressive results in the form of language models capable of solving the protein folding problem to a degree which was considered unthinkable when it was released in the form of Alphafold 2 and RosettaFold.

This happens at a time when the data available in biology is seeing its own revolution with new assays capable of collecting data at new resolutions and in new magnitudes. The first of these databases are the massive amounts of gene sequencing data, an area that has a cost per sequencing development which even leaves behind Moore’s Law and correspondingly the sequences of proteins expressed by these genes.

In terms of proteome analysis the human proteome project released its dataset in 2020 after 10 years of work, in large parts based on the capabilities in mass spectrography available, providing a large annotated human protein database. Genome-Wide-Association-Studies can map between phenotypical measurements and the underlying genes involved in their development.

Single-Cell data refers to the collection of gene expression, chromatin accessibility and proteome data at single-cell resolution at a large scale, allowing the monitoring of cell development from stem cell to fully differentiated cells at all stages of development. As is the case in other fields like image processing and natural language processing, the computer-aided analysis of biological data is currently being pushed forward by advances in artificial intelligence, protein folding being the most prominent example.

On its own, these developments show great promise in unraveling the patterns hidden in the massive datasets collected. However, there are limits to the current approaches in artificial intelligence. Especially the high resource requirements in terms of data and computation are beginning to reach their limits when based on the current foundation models, which is why large research groups at Google, Meta and OpenAI have begun incorporating other modes of model training not relying on model size and large data. Indeed the large requirements limit the amount of researchers capable of building such massive models to a few research labs with the required financial backing to train such resource intensive models.

So while it is great that such models exist and are often available to the public and the rest of the research community for use, its sheer resource demands limit the amount of researchers capable of actually building such models themselves.

The goal of this project is to find a way around this dilemma. We propose that the solution can be found in the field of artificial life in order to model complex biological phenomena, which would also yield the ability to model other complex phenomena ranging from particle physics to population dynamics, ecology, climate and other fields studied by the interdiciplinary complexity science.

The approach taken here is a first principles approach rooted in theoretical biology. If one takes the analysis of complexity in biology by Robert Rosen seriously, one comes to the conclusion that current reductionistic models (necessarily) fall short of explaining complex models because they are ‘too empoverished in entailment’.

What is necessary is a model of the developing phenotype taking into account the interaction of genome, transcriptome, proteome, metabolome and the environment as well as the communication/interpretation/modeling across different layers of abstraction both upwards (emergent behavior through interaction of low-level agent) but also downwards (flow of higher-level-information from higher levels of hierarchy back to lower levels of organisation).

As Mary Jane West-Eberhard writes in her book ‘Developmental Plasticity and Evolution’, such a phenotype-development-based model is essential to both developmental biology as well as to evolutionary biology in order to understand how and where evolutionary pressure drives the evolution of changing phenotypes and eventually genetic changes.

What would this entail, though, in terms of artificial intelligence design? If one considers intelligence as part of a developing phenotype the question arises how its development takes place in space and time. Genes obviously are too limited to describe at detail the entire structure of the organism (genetic bottleneck), but they also seem to contain enough information to drive an initial cell to process its environment in a way to drive the development of the necessary complexity for intelligence over time and also influencing the ongoing processing of environmental information for intelligent behavior like learning as well as other forms of adaptation (as well as a selection for adaptability itself!).

So not encoding the intelligence and adaptation directly but encoding robust strategies for its development in an environment seems to be the path to intelligence in nature. This is in direct contrast to the static supervised learning approach common in current deep learning approaches where a fixed set of rules is learned to solve a singular task given by a fixed dataset. There are ideas for incorporating these features in artificial intelligence models and they are beginning to be explored in the field of artificial life which is dealing with modeling biology using computational means.

Starting with initial approaches like Conway’s game of life, Lindemann systems, boids and genetic algorithms, the central idea in modeling life in the field of artificial life is the notion of emergence, where small units, be they cellular automata, agents or digital ‘genotypes’ interact to produce phenomena which cannot be explained at the level of its low-level components, but are a result of their interaction at massive scale.

What is missing here, the authors of this proposal claim, is the downward path of information flowing from higher levels of hierarchy downwards to adapt the low-level interaction to further the demands of higher levels of organisation. In the case of Conway’s game of life one can see that the three simple rules which drive the cellular automata can give rise to gliders, glider cannons and even a turing-complete computer, but it cannot create complex evolution.

The reason for this is that once higher levels of hierarchy are reached, they cannot adapt the lower levels for further development to grow towards the next hierarchical level in complexity. It is this feedback loop that we intend to incorporate into models to allow them to learn to adapt across grown hierarchical levels to incoming information, to reorganize at all levels to meet the demands of a changing environment as natural systems do.

Even the most flexible of current deep learning models, the transformer, lacks the flexibility to do such things. A model more susceptible to being adapted to these needs is the model of latent diffusion models, where the model does not learn a single output, but learns to process input to its next iteration and only by repeated application of the model does the final output emerge. But again, this processing is fixed and hence not flexible enough.

Another problem in current models is that they need to be trained at the level of complexity desired in the end. The processed data must fit the level of complexity of the training data. Even if out-of-distribution generalisation is possible, solving hard problems while having been only trained on easy ones is not possible for current AI systems.

To solve this dilemma there has recently been developed an approach of training a recursive model on simple and small datasets and allow the model to be run for longer and have it solve more complex problems, extrapolating to more difficult problems by – essentially – processing the problem for longer, or evolving for longer to create a solution. To model complexity one needs a model capable of similar complexity itself, the model must have the necessary capabilities to model the flexibility of the system it is supposed to model.

We contend that current AI systems are lacking in that department. What we intend to build is an AI system truly capable of adaptively reacting to its environment. Not only will we incorporate the notion of downward feedback and multilevel flexibility, we will also build the model in a way which progressively adapts to its environment step by step (and adapts its ability to adapt), we will also make use of learning it recursively so that our model can move beyond its training data to increasing complexity if allowed to run for longer timeframes. This model, if trained on current datasets should be able to extend beyond current models in capability.

The goal is to model biological data like the development of organisms, but it may have become apparent in this proposal that this approach would also be able to model and solve other problems in complexity while also holding the promise of improving the results on current application of AI.

MAIN ORGANIZERS

SPONSORS

ONR Global

The U.S. Office of Naval Research Global (ONR Global) is proud to sponsor the Serendipity Collective, in its second year. Our goal is to provide innovators the opportunity to present their vision for the future of science, society, and humanity.

ONRG provides worldwide science & technology (S&T)-based solutions for current and future naval challenges. Leveraging the expertise of more than 50 scientists, technologists and engineers, ONR Global maintains a physical presence on five continents. The command reaches out to the broad global technical community and the operational fleet/force commands to foster cooperation in areas of mutual interest and to bring the full range of possibilities to the Navy and Marine Corps.

ANDHRA PRADESH MEDTECH ZONE LTD

Andhra Pradesh MedTech Zone Limited (AMTZ) is India’s First Integrated Medical Device Manufacturing Ecosystem, which presents an exciting partnership with the Serendipity Collective. Ideas that pass through the collective may be incubated into the AMTZ program for rapid acceleration through the TRL phases.

The goal of this progressive initiative would be to make Andhra Pradesh an internationally recognized manufacturing hub for medical devices, help in national agenda of import substitution, make Andhra Pradesh a leader in medical technology exports, generate employment, and contribute to volume generated cost reduction of medical devices for patients.

This project has received funding from the European Union’s HORIZON Teaming for Excellence programme under grant agreement 101060066

BE PART OF
THE COLLECTIVE

IDEATEPLUS | SPRIND | ONR GLOBAL
Copyright © 2023 IdeatePlus, All rights reserved.
Terms of Service | Privacy Policy